Mosapramine (Cremin) is an atypical antipsychotic of the iminodibenzyl class primarily used in Japan for the treatment of schizophrenia.[1][2][3] It is a potent dopamine antagonist with high affinity to the D2, D3, and D4 receptors,[4] and with moderate affinity for the 5-HT2 receptors.[5]

See also

References

  1. ↑ Takahashi N, Terao T, Oga T, Okada M (1999). "Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia". Neuropsychobiology. 39 (2): 81–85. doi:10.1159/000026565. PMID 10072664. S2CID 6554048.
  2. ↑ Miyamoto S (2010). "Mosapramine". In Stolerman IP (ed.). Encyclopedia of Psychopharmacology. Berlin, Heidelberg: Springer. p. 76. doi:10.1007/978-3-540-68706-1_1839. ISBN 978-3-540-68706-1. Retrieved 21 March 2022.
  3. ↑ Kishi T, Matsunaga S, Matsuda Y, Iwata N (2014). "Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine". Neuropsychiatric Disease and Treatment. 10: 2339–2351. doi:10.2147/NDT.S73464. PMC 4266422. PMID 25525363.
  4. ↑ Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T (May 1996). "[The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 107 (5): 247–253. doi:10.1254/fpj.107.247. PMID 8690306.
  5. ↑ Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, et al. (February 1995). "Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy". Neuropsychopharmacology. 12 (1): 57–64. doi:10.1016/0893-133X(94)00064-7. PMID 7766287.
source: https://en.wikipedia.org/wiki/Mosapramine